Showing 71-80 of 1716 results for "".
Possible Reasons for Low Search Rankings of your Dermatology Practice Website
https://practicaldermatology.com/topics/practice-management/possible-reasons-for-low-search-rankings-of-your-dermatology-practice-website/19626/Improving the search engine ranking of your dermatology practice website helps you expand your outreach rapidly. This Ekwa Marketing video contains information related to the five most important aspects related to your website that you should audit to help improve its search engine rankings.Science of Skincare Summit 2024:The Latest in Exosomes
https://practicaldermatology.com/conferences/science-skincare-summit-2024/science-of-skincare-summit-2024-the-latest-in-exosomes/29450/Practical Dermatology talks with Todd Schlesinger, MD, a dermatologist and Mohs surgeon, and a member of the Editorial Board, about the latest updates in exosomes and what to expect next. This video was recorded at the Science of Skincare Summit in Austin.The Latest in Blistering Diseases
https://reachmd.com/programs/practical-dermatology/the-latest-in-blistering-diseases/33007/Kim B. Yancey, MD, a professor of dermatology at UT Southwestern Medical Center in Dallas, talks about current treatments and techniques for blistering diseases, focusing specifically autoimmune blistering diseases.AI: What it Means for Medicine
https://practicaldermatology.com/topics/practice-management/ai-what-it-means-for-medicine/19636/Justin Ko, MD, MBA shares his thoughts on how artificial and augmented intelligence will impact dermatology and discusses the AAD’s recent position statement on this technology.Optimizing Content Curation
https://practicaldermatology.com/topics/practice-management/optimizing-content-curation/18760/You've started curating content to improve SEO. Now you need to be sure you are doing it right. This Ekwa educational video explains, offering tips for automating and optimizing the process.Anti-OX40 Ligand Antibody Trials
https://practicaldermatology.com/series/updates-atopic-dermatitis/anti-ox40-ligand-antibody-trials/29531/Lead study author Stephan Weidinger, MD, PhD, Director of the Department of Dermatology and Allergy at the University Hospital Schleswig-Holstein, discusses the phase 2b STREAM-AD trial, evaluating amlitelimab in adult patients with moderate-to-severe atopic dermatitis.PDRN and Regenerative Medicine Update
https://practicaldermatology.com/conferences/science-of-skin-summit-2025/pdrn-regenerative-medicine-update/39739/Suneel Chilukuri, MD, covers the latest in polydeoxyribonucleotide (PDRN) therapies and regenerative medicine applications in dermatology. This video was recorded at the Science of Skin Summit in Austin, TX.Radiesse for Hands, Alevicyn Cleared
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-radiesse-for-hands-alevicyn-cleared/18898/Merz gets FDA approval for Radiesse for hand augmentation and releases data comparing Xeomin to Botox. Heidi Waldorf, MD, FAAD and Michael Gold, MD, FAAD, comment. Also in this edition, Galderma participate in a White House forum on antibiotic stewardship, and the FDA gives 510(k) clearance to AleviImplementing Skincare Solutions in Practice
https://practicaldermatology.com/topics/practice-management/implementing-skincare-solutions-in-practice/18902/Leslie Baumann, MD, FAAD discusses the challenges of offering effective skincare recommendations to patients and shares some of the practical solutions she has implemented in her practice. The author of "The Skin Type Solution," describes how she chooses skincare for each individual patient and giveDermWire TV: Kysse Approved, Sunscreen Use Trends, AbbVie/Allergan Deal
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwire-tv-kysse-approved-sunscreen-use-trends-abbvieallergan-deal/19812/Galderma's Restylane Kysse is now FDA approved for lip augmentation and the correction of wrinkles around the upper lips in adults. Americans understand that sunscreen use is important to protect the skin, but they still don’t use SPF regularly, AAD data reveal. AbbVie has completed its acquisition